Table 4.

Effect of MECz on percentage of cell viability, apoptosis and cell cycle arrest in MDA-MB-231 and MCF-7 breast cancer cells

MECz treatment (µg/mL)	Cell viability (% of live cells)		Apoptosis (% of dead cells)		Cell cycle (S phase)		Cell cycle (G2/M phase)
	MDA-MB-231	MCF-7	MDA-MB-231	MCF-7	MDA-MB-231	MCF-7	MDA-MB-231	MCF-7
Control	94.5	98.5	0.43	0.35	18.8	17.6	9.8	9.7
DMSO	94.3	97.5	0.79	0.20	17.6	16.5	9.5	9.4
MECz-5 µg/mL	78.1*	89.9*	2.05*	0.85	18.3	17.5	11.2	11.5*
MECz-10 µg/mL	74.7*	76.5*	7.15*	9.10*	18.0	17.1	13.9*	14.2*
MECz-15 µg/mL	65.5*	64.8*	13.75**	18.80**	17.7	16.5	23.1*	23.3*
MECz-20 µg/mL	58.5**	59.6**	21.75**	28.75**	15.7*	16.3*	28.3**	28.1**
MECz-25 µg/mL	53.4***	49.0***	37.96***	48.10***	12.9**	13.5**	32.1***	32.3***
Doxorubicin	51.5***	47.5***	38.56***	49.25***	12.6**	13.2**	33.4***	33.5***

Data are represented as mean ± SD of triplicates, treated groups were compared with control using one-way ANOVA test, the values of DMSO (non-significant) and the values of treated groups are significant at *p < 0.05, **p < 0.01 and ***p < 0.001, respectively

Control untreated cells; DMSO vehicle control; MECz methanol extract of Capparis zeylanica; Doxorubicin standard drug